[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Grifols S.A. ADR (GRFS)

Grifols S.A. ADR (GRFS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,349,320
  • Shares Outstanding, K 680,575
  • Annual Sales, $ 8,513 M
  • Annual Income, $ 454,820 K
  • EBIT $ 1,417 M
  • EBITDA $ 1,926 M
  • 60-Month Beta 0.66
  • Price/Sales 0.63
  • Price/Cash Flow 5.56
  • Price/Book 0.58

Options Overview Details

View History
  • Implied Volatility 72.55% (+33.68%)
  • Historical Volatility 32.90%
  • IV Percentile 61%
  • IV Rank 21.83%
  • IV High 224.36% on 02/26/26
  • IV Low 30.14% on 08/12/25
  • Expected Move (DTE 17) 0.30 (3.67%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 94
  • Volume Avg (30-Day) 185
  • Put/Call OI Ratio 0.83
  • Today's Open Interest 7,364
  • Open Int (30-Day) 6,773
  • Expected Range 7.80 to 8.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.27
  • Number of Estimates 1
  • High Estimate $0.27
  • Low Estimate $0.27
  • Prior Year $0.19
  • Growth Rate Est. (year over year) +42.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.00 +15.86%
on 07/14/26
8.37 -3.11%
on 07/30/26
+0.95 (+13.27%)
since 07/02/26
3-Month
6.96 +16.52%
on 07/01/26
8.47 -4.19%
on 05/07/26
-0.12 (-1.46%)
since 05/04/26
52-Week
6.96 +16.52%
on 07/01/26
10.84 -25.15%
on 08/14/25
-2.61 (-24.35%)
since 08/04/25

Most Recent Stories

More News
Grifols' Transformation Narrative Depends on Investors Ignoring the Plasma Economics

Barchart Research What to Expect from GRFS Earnings GRFS Generated July 31, 2026 Current Price $7.87 EPS Estimate $$0.27 Consensus Rating Moderate Buy Average Move 3.84% Grifols' Transformation Narrative...

GRFS : 8.12 (+3.31%)
Grifols Reports Next Week With Restructuring Questions Still Unanswered

Barchart Research What to Expect from GRFS Earnings GRFS Generated July 24, 2026 Current Price $7.58 EPS Estimate $$0.28 Consensus Rating Moderate Buy Average Move 3.84% Grifols Reports Next Week With...

GRFS : 8.12 (+3.31%)
Grifols Q1 Earnings Call Highlights

Grifols (NASDAQ:GRFS) executives said the company began 2026 in line with its internal plans, pointing to continued strength in immunoglobulins, early progress in expanding plasma sourcing outside the...

GRFS : 8.12 (+3.31%)
New Strong Sell Stocks for July 31st

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Creative Medical Technology Holdings, Inc. CELZ is a commercial-stage biotechnology company. The Zacks Consensus Estimate for its...

WHR : 44.83 (+14.33%)
GRFS : 8.12 (+3.31%)
CELZ : 0.6464 (-1.19%)
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?

ADMA Biologics ADMA and Grifols GRFS are leading producers of plasma-derived therapies, specializing in immunoglobulin treatments for immunodeficiencies and other conditions.ADMA Biologics markets plasma-derived...

GRFS : 8.12 (+3.31%)
ADMA : 9.00 (+2.97%)
Grifols Stock Declines After Brookfield Drops Buyout Offer

Shares of Grifols GRFS lost over 7% on Wednesday after the company announced that Canada-based Brookfield Asset Management has withdrawn its plan to acquire it.Both parties likely failed to arrive at a...

CTMX : 3.31 (+4.42%)
CSTL : 31.17 (+2.57%)
GRFS : 8.12 (+3.31%)
SPRO : 1.2150 (+5.65%)
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

Shares of Grifols GRFS lost over 8% on Tuesday after the company’s board refused to endorse Canada-based Brookfield Asset Management’s offer to acquire its outstanding share capital for €6.45 billion...

CTMX : 3.31 (+4.42%)
CSTL : 31.17 (+2.57%)
GRFS : 8.12 (+3.31%)
SPRO : 1.2150 (+5.65%)
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain

/PRNewswire/ -- DelveInsight's 'Dry Eye Disease Pipeline Insight – 2023' report provides comprehensive global coverage of pipeline dry eye disease therapies in...

GRFS : 8.12 (+3.31%)
Why Shares of Grifols Were Up Tuesday

The company gave first-quarter numbers.

GRFS : 8.12 (+3.31%)
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

/PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived...

GRFS : 8.12 (+3.31%)
GRF : 10.43 (-1.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience...

See More

Key Turning Points

3rd Resistance Point 8.05
2nd Resistance Point 7.98
1st Resistance Point 7.92
Last Price 8.12
1st Support Level 7.78
2nd Support Level 7.71
3rd Support Level 7.65

See More

52-Week High 10.84
Fibonacci 61.8% 9.35
Fibonacci 50% 8.90
Fibonacci 38.2% 8.44
Last Price 8.12
52-Week Low 6.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.